Autolus Therapeutics PLC (NASDAQ: AUTL) is a clinical-stage biopharmaceutical company that develops programmed T cell therapies for cancer. Revenue is generated through product sales of its approved CAR-T therapy AUCATZYL, with additional arrangements including a License and Option Agreement with BioNTech SE executed February 6, 2024. AUCATZYL received formal CMS reimbursement coding under the Healthcare Common Procedure Coding System and Hospital Outpatient Prospective Payment System, effective April 1, 2025. The company is incorporated under English law, lists American Depositary Shares on Nasdaq, and operates manufacturing and research facilities including a site at The Nucleus Marshgate, Stevenage, United Kingdom. Autolus reports as a non-accelerated filer under SEC rules as of the 10-K filed March 27, 2026.

Revenue model

Product revenue from sales of AUCATZYL, recognized under ASC Topic 606 when the customer obtains control of the product. The company also entered a License and Option Agreement with BioNTech SE (dated February 6, 2024), which may provide licensing-related consideration. R&D tax relief claims have historically been made under the UK SME program; for the period ending December 31, 2025, the company expects to claim under the merged RDEC regime instead.

Products and services

AUCATZYL is the company's commercial CAR-T cell therapy product. The company also has a pipeline of programmed T cell product candidates in development. A supply agreement with Miltenyi Biotec B.V. & Co. KG supports manufacturing.

Customers and end markets

End markets are oncology patients treated at hospital outpatient and inpatient settings in the United States. CMS formalized reimbursement for AUCATZYL on April 1, 2025, covering patients on government programs. No customer concentration data is disclosed in the excerpts.

Value-chain role

Autolus develops and manufactures CAR-T cell therapies internally, with contract supply support from Miltenyi Biotec B.V. & Co. KG. The company operates its own manufacturing facility in Stevenage, UK. It holds IP through patents and has licensing arrangements with BioNTech SE.

Geographic exposure

Primary operations are in the United Kingdom, with commercial activity in the United States. The company transfers personal data across the EEA, UK, Switzerland, and the United States in the course of its operations.

Source: SEC 10-K, filed 2026-03-27

Industry: Biological Products, (No Diagnostic Substances) Peers: Achilles Therapeutics plc Adaptimmune Therapeutics PLC Centessa Pharmaceuticals PLC Compass Pathways PLC Barinthus Biotherapeutics PLC